Clinical Trial Update: Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating osimertinib for non-small cell lung cancer with EGFR exon 20 alterations; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Status: RECRUITING